Vol 2 (April 25, 2024): AME Clinical Trials Review

Editorial Commentary 
ADAURA: redefining the role of target therapy in resectable lung adenocarcinoma
Jairo A. Zuluaga, Leonardo Rojas, Oscar Arrieta, Andrés F. Cardona
AME Clinical Trials Review  
2024;
2:
26  
Editorial Commentary 
Is osimertinib effective as 2nd line treatment in T790M-negative EGFR mutant NSCLC?
Panagiota Economopoulou, Ioannis Kotsantis, Amanda Psyrri
AME Clinical Trials Review  
2024;
2:
25  
Editorial Commentary 
New treatment options for crizotinib-resistant ALK-positive non-small cell lung cancer patients
Akikazu Kawase
AME Clinical Trials Review  
2024;
2:
23  
Editorial Commentary 
Neoadjuvant osimertinib: a promising therapeutic option for locally advanced EGFR-mutant lung adenocarcinoma
Shinji Yuhara, Yoshihisa Shimada, Masaaki Sato
AME Clinical Trials Review  
2024;
2:
21  
Editorial Commentary 
Chest tube after lung resection—a small change to a great benefit
Joao Santos Silva, Pierre-Emmanuel Falcoz
AME Clinical Trials Review  
2024;
2:
20  
Editorial Commentary 
How to navigate an increasingly heterogeneous spectrum of resistance mechanisms in oncogene driven non-small cell lung cancer?
Charlotte De Bondt, Paul Van Schil
AME Clinical Trials Review  
2024;
2:
19  
Editorial Commentary 
Genomic and molecular considerations for sotorasib treatment in KRAS G12C-mutant non-small cell lung cancer
Kevin Lu, Hatim Husain
AME Clinical Trials Review  
2024;
2:
18  
Editorial Commentary 
Utilization of pharmacokinetics in the dosing of pembrolizumab in non-small cell lung cancer
Lauren Tagliaferro Epler, Joel W. Neal
AME Clinical Trials Review  
2024;
2:
17  
Editorial Commentary 
Breaking barriers: bridging the gap in lung cancer trials through inclusive representation
Julian A. Marin-Acevedo, Sonam Puri
AME Clinical Trials Review  
2024;
2:
16  
Editorial Commentary 
Optimizing the role of immunotherapy in the management of resectable non-small cell lung cancer
Laercio DaSilva, Meredith J. McAdams, Arun Rajan
AME Clinical Trials Review  
2024;
2:
15  
Editorial Commentary 
The ELUCIDATE trial: a step closer to complete resection of lung tumors
Arvindran Alaga, Masahide Oki
AME Clinical Trials Review  
2024;
2:
14  
Editorial Commentary 
NEOSTAR platform trial: neoadjuvant dual immunotherapy plus chemotherapy—more is better?
Shuai Wang, Haiying Cheng
AME Clinical Trials Review  
2024;
2:
13  
Editorial Commentary 
Immunotherapy as first-line treatment in locally advanced/metastatic and previously untreated squamous cell lung cancer: which advances?
Noemi Maria Giorgiano, Francesca Pentimalli, Giovanni Natale, Carminia Maria Della Corte, Floriana Morgillo, Alfonso Fiorelli
AME Clinical Trials Review  
2024;
2:
11